ORx
ORx Pharmaceuticals is an advanced drug delivery specialty pharmaceutical company focused on designing, developing, and clinically testing new and advanced dosage forms of promising drug compounds. Their mission is to improve clinical performance and patient care through innovative technologies that optimize bioavailability and drug delivery. They develop proprietary pharmaceutical products, enhance bio-performance, and expand technology platforms, aiming to create value-added drug products with lower development risks and quicker market access.
Industries
Nr. of Employees
small (1-50)
ORx
800 – 55 Town Centre Court, Toronto, Ontario, M1P 4X4, Canada
Patents
Products
GlycoBien CR
A once-daily oral hypoglycemic formulation intended to lower blood glucose and reduce glucose spikes; indicated for prediabetics and newly diagnosed Type 2 diabetes patients. Reported clinical phase: Phase II.
Leptivia CR
A repurposed oral anti-obesity formulation derived from an existing safe molecule designed to promote weight loss through increased satiety and appetite suppression. Reported clinical phase: Phase I.
Orazephin CR
An oral formulation of an intravenously used broad-spectrum antibiotic (ceftriaxone) intended to enable oral administration of a traditionally parenteral agent. Reported clinical phase: Phase I.
HydroMatrix platform
A platform technology for oral controlled-release dosage forms that uses interacting polymers to generate pressure-modulated release, enabling zero-order release kinetics, programmable delay, and multi-drug release profiles; described as simple to implement and scalable.
OraRem platform
A bio-enabling oral delivery and targeting platform that uses delivery agents to enable membrane transport and improve tissue distribution of poorly absorbable therapeutic molecules via in-situ reverse-micelle formation.
GlycoBien CR
A once-daily oral hypoglycemic formulation intended to lower blood glucose and reduce glucose spikes; indicated for prediabetics and newly diagnosed Type 2 diabetes patients. Reported clinical phase: Phase II.
Leptivia CR
A repurposed oral anti-obesity formulation derived from an existing safe molecule designed to promote weight loss through increased satiety and appetite suppression. Reported clinical phase: Phase I.
Orazephin CR
An oral formulation of an intravenously used broad-spectrum antibiotic (ceftriaxone) intended to enable oral administration of a traditionally parenteral agent. Reported clinical phase: Phase I.
HydroMatrix platform
A platform technology for oral controlled-release dosage forms that uses interacting polymers to generate pressure-modulated release, enabling zero-order release kinetics, programmable delay, and multi-drug release profiles; described as simple to implement and scalable.
OraRem platform
A bio-enabling oral delivery and targeting platform that uses delivery agents to enable membrane transport and improve tissue distribution of poorly absorbable therapeutic molecules via in-situ reverse-micelle formation.
Services
Out-licensing of developed drug products and platform IP to pharmaceutical and biotechnology companies.
Contracted feasibility studies that screen challenging compounds to identify formulation strategies and provide an option for license of the development outcome.
Collaborative development of NCEs to address oral bioavailability challenges and support life-cycle management.
Services to reformulate marketed drugs to create differentiated products that can extend market exclusivity and support commercialization strategies.
Out-licensing of developed drug products and platform IP to pharmaceutical and biotechnology companies.
Contracted feasibility studies that screen challenging compounds to identify formulation strategies and provide an option for license of the development outcome.
Collaborative development of NCEs to address oral bioavailability challenges and support life-cycle management.
Services to reformulate marketed drugs to create differentiated products that can extend market exclusivity and support commercialization strategies.
Expertise Areas
- Oral drug delivery platforms
- Controlled-release formulation development
- Oral bio-enabling for poorly absorbable molecules
- Clinical development and trial execution for reformulated products
Key Technologies
- Controlled-release oral matrix systems
- Hydrostatic pressure-modulated polymer matrices
- Reverse-micelle mediated oral delivery
- Oral bio-enabling carrier systems
News & Updates
Patents Granted
1+ patents granted in 1+ countries.
Patents Granted
1+ patents granted in 1+ countries.